A Phase 4 interventional study of Tadalafil and Placebo in Erectile Dysfunction, sponsored by Eli Lilly and Company. Completed at 52 sites in 10 countries. Open to male participants aged 18 Years to 67 Years. Per ClinicalTrials.gov, last updated 2014-01-14.
Sponsored by Eli Lilly and Company · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 57 studies testing tadalafil in Erectile Dysfunction — 9 open to participants now, 9 under way, 3 of them phase 3. Tadalafil · Erectile Dysfunction.
Among the 57 studies testing tadalafil in Erectile Dysfunction, this one is the 10th largest by enrollment of the 56 interventional ones that give a count, is one of 5 that started in 2009, is one of 26 in phase 4, and was the 25th registered.
702 studies on the registry are indexed under Erectile Dysfunction; 125 are open to participants now.
Browse Erectile Dysfunction studies →9 of the 57 studies testing tadalafil in Erectile Dysfunction are open now, in 4 countries. Recruiting first, the newest first:
Surgical Outcomes Research Centre (SOuRCe) · Sites in Australia
Ages 18+ · Men only
Al-Azhar University · Sites in Egypt
Ages 18–70 · Men only
Beni-Suef University · Sites in Egypt
Ages 30–70 · Men only
Mansoura University · Sites in Egypt
Ages 21+ · Men only
Aswan University Hospital · Sites in Egypt
Ages 21+ · Men only
By country, each count listing its studies:
Tadalafil: first FDA approval 2003 (CIALIS), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →
Of the 78 Erectile Dysfunction studies recruiting now, 31 (40%) set no upper age limit and 34 (44%) stop at 75 or younger; 2 take children under 18; 7 take healthy volunteers.
This study: 18 Years to 67 Years · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
57 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 6 · Phase 3 21 · Phase 4 26
First in 2002; this study’s year is marked. 5 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 583 is above the median of 70 across 551 interventional studies indexed under Erectile Dysfunction.
Median enrollment 199 across the 56 interventional studies. Of the 42 that completed or were terminated, 13 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
32 of 57 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
28 studies in Erectile Dysfunction by Eli Lilly and Company: none open now, none under way, none of them phase 3. Of 28 finished, 14 (50%) have results posted.
Among the 28 studies in Erectile Dysfunction by Eli Lilly and Company, this one is the 9th largest by enrollment, is one of 4 that started in 2009, is one of 12 in phase 4, and was the 20th registered.
Eli Lilly and Company’s Erectile Dysfunction studies by the year they started, since 2002.
3 of the studies testing tadalafil in Erectile Dysfunction that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07642505Beni-Suef UniversityL-Citrulline and Tadalafil for Mild to Moderate Erectile Dysfunction | 2026-11 |
| NCT07391579Mansoura UniversityDaily Tadalafil 5 mg Combined With On-Demand Sildenafil 100 mg for Treatment of Erectile Dysfunction in PDE-5I Non Responder Patients | 2026-12 |
| NCT07753720Al-Azhar UniversityDaily Tadalafil as Adjunctive Therapy Versus Monotherapy for PDE5 Inhibitor-Resistant Erectile Dysfunction | 2027-06-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 57 studies testing tadalafil in Erectile Dysfunction, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eli Lilly and Company’s 28 in Erectile Dysfunction:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The study will include patients with localized prostate cancer who experience erectile dysfunction following bilateral nerve-sparing radical prostatectomy. Patients will be randomly assigned to three treatment arms: Tadalafil 5 mg once a day, Tadalafil 20 mg on demand (prior to anticipated sexual activity), and placebo. Patients will stay on therapy for 9 months and after withdrawal of medication for 6 weeks, patients will be evaluated for recovery of unassisted erectile function (without medication). An open-label extension for three months will evaluate the responsiveness of all patients to Tadalafil 5 mg once a day. Further objectives are to evaluate the treatment satisfaction of the respective therapies.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
After the treatment period and 6-week study Drug-Free Period, all participants can continue on study in an optional 5-mg tadalafil 3-month Open-Label Period.
Drug: Tadalafil
After the treatment period and 6-week study Drug-Free Period, all participants can continue on study in an optional 5-mg tadalafil 3-month Open-Label Period.
Drug: Tadalafil
After the treatment period and 6-week study Drug-Free Period, all participants can continue on study in an optional 5-mg tadalafil 3-month Open-Label Period.
Drug: Placebo
Administered by mouth for 9 months
Also known as: Cialis, LY450190
Administered by mouth, daily or on demand for 9 months
Percentage of Participants With a Score of Greater Than or Equal to 22 in the Erectile Function (EF) Domain of the International Index of Erectile Function (IIEF) Questionnaire
Self-reported erectile function during the past 4 weeks. IIEF- EF is the sum of Questions 1-5 and 15 of the IIEF. Questions 1-5 are scored 0 (no sexual activity for Question 1, no sexual stimulation for Question 2 and did not attempt intercourse for Questions 3-5) to 5 (high erectile function) and Question 15 is scored 1 (very low confidence) to 5 (very high confidence), for a total score ranging from 1 to 30. Higher scores represent better erectile function. Data presented are the percentage of participants with an IIEF-EF Total Score greater than or equal to (≥) 22.
Time frame: Month 10.5
Percentage of Participants With a Score of Greater Than or Equal to 22 in the International Index of Erectile Function- Erectile Function (IIEF-EF) Domain
Self-reported erectile function during the past 4 weeks. IIEF- EF is the sum of Questions 1-5 and 15 of the IIEF. Questions 1-5 are scored 0 (no sexual activity for Question 1, no sexual stimulation for Question 2 and did not attempt intercourse for Questions 3-5) to 5 (high erectile function) and Question 15 is scored 1 (very low confidence) to 5 (very high confidence), for a total score ranging from 1 to 30. Higher scores represent better erectile function. Data presented are the percentage of participants with an IIEF-EF Total Score greater than or equal to (≥) 22.
Time frame: Month 9 and Month 13.5
Change From Baseline to Endpoint in the International Index of Erectile Function- Erectile Function (IIEF-EF) Total Score
Self-reported erectile function during the past 4 weeks. IIEF- EF is the sum of Questions 1-5 and 15 of the IIEF. Questions 1-5 are scored 0 (no sexual activity for Question 1, no sexual stimulation for Question 2 and did not attempt intercourse for Questions 3-5) to 5 (high erectile function) and Question 15 is scored 1 (very low confidence) to 5 (very high confidence), for a total score ranging from 1 to 30. Higher scores represent better erectile function. The Mixed Model for Repeated Measures (MMRM) analysis was used to calculate Least Squares (LS) mean and 95% confidence interval (CI). LS mean values are adjusted for baseline score, treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p\<0.10).
Time frame: Randomization (Baseline), Months 9 and 10.5 and 13.5
Change From Baseline to Endpoint in the International Index of Erectile Function (IIEF) Domains (Intercourse Satisfaction Domain, Orgasmic Function Domain, Sexual Desire Domain, Overall Satisfaction Domain)
Self-reported overall satisfaction during past 4 weeks. Orgasmic function score is sum of Questions (Q)9 and 10 of IIEF. Scores range from 0 (no sexual stimulation or intercourse) to 5 (high orgasm) for each Q, total 0 to 10. Sexual desire score is sum of Q11 and 12 of IIEF. Scores range from 1 (low/no desire) to 5 (high desire) for each Q, total 2 to 10. Intercourse satisfaction score is sum of Q6, 7 and 8 of IIEF. Scores range from 0 (no attempts for Q6, did not attempt intercourse for Q7 and no intercourse for Q8) to 5 (high satisfaction) for each Q, total 0 to 15. Overall satisfaction score is sum of Q13 and 14 of IIEF. Scores range from 1 (low/no satisfaction) to 5 (high satisfaction) for each Q, total 2 to 10. Higher total scores for each domain indicate higher function. MMRM analysis was used to calculate LS mean and 95% CI. LS mean values are adjusted for baseline, treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p\<0.10).
Time frame: Randomization (Baseline), Months 9 and 10.5 and 13.5
Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS) Questionnaire Mean Score
The EDITS questionnaire is a validated questionnaire consisting of 11 questions evaluating self-reported satisfaction with the erectile dysfunction (ED) treatment. Responses were based on the experiences during the previous 4 weeks. Each question is rated on a scale of 0 (extremely low treatment satisfaction) to 4 (extremely high treatment satisfaction). The EDITS mean score was obtained by adding each individual result for all questions, dividing by the number of questions answered. The mean scores range from 0 (extremely low treatment satisfaction) to 4 (extremely high satisfaction). The Mixed Model for Repeated Measures (MMRM) analysis was used to calculate Least Squares (LS) mean and 95% Confidence Interval (CI). LS mean values are adjusted for treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p\<0.10).
Time frame: Months 9 and 13.5
Change From Baseline in Self Esteem and Relationship (SEAR) Questionnaire Score
The SEAR questionnaire is a participant-reported measure of psychosocial outcomes in men with erectile dysfunction (ED). It consists of 14 items. Sexual Relationship domain consists of 8 items (items 1-8). Items 2-8 are rated on a scale of 1 (Never) to 5 (Always), whereas item 1 is reverse scored (1=Always and 5=Never). The total scores for sexual relationship domain range from 8-40 with higher scores indicating better relationship. Self-Esteem subdomain contains items 9 through 12 rated on a scale of 1 (no/low self-esteem) to 5 (high self-esteem). Total scores for Self-Esteem subscale range from 4-20 with higher scores indicating higher self-esteem. The Mixed Model for Repeated Measures (MMRM) analysis was used to calculate Least Squares (LS) mean and 95% Confidence Interval (CI). LS mean values are adjusted for baseline domain score, treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p\<0.10).
Time frame: Randomization (Baseline), Months 9 and 13.5
Global Assessment Questions (GAQ) Question 1 at Month 9
GAQ Question 1: Choose the one number which best describes how you perceive your ability to achieve and maintain your erections now, compared to how it was before you began taking medication in this study. Responses range from very much better (1) to very much worse (7).
Time frame: Month 9
Global Assessment Question (GAQ) Question 1 at Month 13.5
GAQ Question 1: Choose the one number which best describes how you perceive your ability to achieve and maintain your erections now, compared to how it was before you began taking medication in this study. Responses range from very much better (1) to very much worse (7).
Time frame: Month 13.5
Global Assessment Question (GAQ) Question 2 at Month 9
GAQ Question 2: Choose the one number which best describes how you perceive your sexual life is now, compared to how it was before you began taking medication in this study. Responses range from very much better (1) to very much worse (7).
Time frame: Month 9
Global Assessment Question (GAQ) Question 2 at Month 13.5
GAQ Question 2: Choose the one number which best describes how you perceive your sexual life is now, compared to how it was before you began taking medication in this study. Responses range from very much better (1) to very much worse (7).
Time frame: Month 13.5
Residual Erectile Function (REF) at Baseline
The participant is asked to rate the hardness of his erection using a 5-point grading system, with 0 (penis does not enlarge), 1 (penis is larger but not hard), 2 (penis is hard but not enough for penetration), 3 (penis is hard enough for penetration but not completely hard), 4 (penis is completely hard and fully rigid.)
Time frame: Baseline
Residual Erectile Function (REF) at Month 2
The participant is asked to rate the hardness of his erection using a 5-point grading system, with 0 (penis does not enlarge), 1 (penis is larger but not hard), 2 (penis is hard but not enough for penetration), 3 (penis is hard enough for penetration but not completely hard), 4 (penis is completely hard and fully rigid.)
Time frame: Month 2
Residual Erectile Function (REF) at Month 5
The participant is asked to rate the hardness of his erection using a 5-point grading system, with 0 (penis does not enlarge), 1 (penis is larger but not hard), 2 (penis is hard but not enough for penetration), 3 (penis is hard enough for penetration but not completely hard), 4 (penis is completely hard and fully rigid.)
Time frame: Month 5
Residual Erectile Function (REF) at Month 9
The participant is asked to rate the hardness of his erection using a 5-point grading system, with 0 (penis does not enlarge), 1 (penis is larger but not hard), 2 (penis is hard but not enough for penetration), 3 (penis is hard enough for penetration but not completely hard), 4 (penis is completely hard and fully rigid.)
Time frame: Month 9
Residual Erectile Function (REF) at Month 10.5
The participant is asked to rate the hardness of his erection using a 5-point grading system, with 0 (penis does not enlarge), 1 (penis is larger but not hard), 2 (penis is hard but not enough for penetration), 3 (penis is hard enough for penetration but not completely hard), 4 (penis is completely hard and fully rigid.)
Time frame: Month 10.5
Residual Erectile Function (REF) at Month 13.5
The participant is asked to rate the hardness of his erection using a 5-point grading system, with 0 (penis does not enlarge), 1 (penis is larger but not hard), 2 (penis is hard but not enough for penetration), 3 (penis is hard enough for penetration but not completely hard), 4 (penis is completely hard and fully rigid.)
Time frame: Month 13.5
Change From Baseline in 'Yes' Answers to Questions 1 to 5 of the Sexual Encounter Profile (SEP)
Participant-assessed diary has 5 questions: Question (Q)1: erection achievement, Q2: successful penetration, Q3: successful intercourse, Q4: satisfied with erection, and Q5: satisfied with sexual experience) for each sexual encounter made over a specified period of time. SEP Q1-Q5 scores were determined as the percentage of 'Yes' responses to each of the 5 questions out of all sexual attempts recorded during the time period. The Mixed Model for Repeated Measures (MMRM) analysis was used to calculate Least Squares (LS) mean and 95% confidence interval (CI). LS mean values are adjusted for treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p\<0.10).
Time frame: Randomization (Baseline), Months 9 and 10.5 and 13.5
Change From Baseline in 'Yes' Answers to Morning Erections
The participants were asked to complete the morning erections diary every morning during the 4-week period before randomization and during the 6-week, Drug-Free, Washout Period. Data presented are the changes in the participant's percentage of "yes" responses relative to the number of days the question was answered during treatment. The analysis of covariance (ANCOVA) was used to calculate Least Square (LS) mean and 95% confidence interval (CI). LS mean values are adjusted for treatment, baseline morning erections frequency, age group and country.
Time frame: Randomization (Baseline), Month 10.5
Standardized Morning Erections Question (SMEQ) Score at Month 2
Participants evaluated the frequency of their morning erections during the past 3-month period by answering the SMEQ ("Do you ever wake up with an erection") using a 4-point grading system ranging from 0 (Yes, regularly) to 3 (never).
Time frame: Month 2
Standardized Morning Erections Question (SMEQ) Score at Month 9
Participants evaluated the frequency of their morning erections during the past 3-month period by answering the SMEQ ("Do you ever wake up with an erection") using a 4-point grading system ranging from 0 (Yes, regularly) to 3 (never).
Time frame: Month 9
Standardized Morning Erections Question (SMEQ) Score at Month 13.5
Participants evaluated the frequency of their morning erections during the past 3-month period by answering the SMEQ ("Do you ever wake up with an erection") using a 4-point grading system ranging from 0 (Yes, regularly) to 3 (never).
Time frame: Month 13.5
Change From Baseline in 26-item Expanded Prostate Cancer Index Composite (EPIC-26) Questionnaire Score
EPIC-26 (participants) contains 26 items and 5 domains: Urinary Incontinence (Items 1-4), Urinary Irritative/Obstructive (Items 5-8), Bowel (Items 10-15), Sexual (Items 16-21), and Hormonal (Items 22-26). Response options for each EPIC item form a Likert scale, and multi-item scale scores are transformed linearly to a 0 to 100 scale for each domain, with higher scores representing better health-related quality of life. Responses are based on experiences during the previous 4 weeks. The Mixed Model for Repeated Measures (MMRM) analysis was used to calculate Least Squares (LS) mean and 95% confidence interval (CI). LS mean values are adjusted for baseline domain score, treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p\<0.10).
Time frame: Randomization (Baseline), Months 9 and 13.5
Change in Penile Length and Girth
Measurements were performed with the penis in the flaccid state. The stretched penile length was measured from the tip of the glans to the pubopenile skin junction while applying tension to maximally stretch the penis. The penile circumference at midshaft was measured. All measurements were taken with a paper ruler to the nearest 0.5 centimeter (cm). The analysis of covariance (ANCOVA) was used to calculate Least Square (LS) mean and 95% confidence interval (CI). LS mean values are adjusted for treatment, baseline, age group and country.
Time frame: Randomization (Baseline), Month 9
| Milestone | Screen - BNSRP | Tadalafil 5 mg OaD | Tadalafil 20 mg PRN | Placebo |
|---|---|---|---|---|
| Started | 583 | 0 | 0 | 0 |
| Completed | 423 | 0 | 0 | 0 |
| Not completed | 160 | 0 | 0 | 0 |
| Withdrew: Entry criteria not met | 105 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 49 | 0 | 0 | 0 |
| Withdrew: Protocol deviation | 3 | 0 | 0 | 0 |
| Withdrew: Adverse event | 2 | 0 | 0 | 0 |
| Withdrew: Physician decision | 1 | 0 | 0 | 0 |
| Milestone | Screen - BNSRP | Tadalafil 5 mg OaD | Tadalafil 20 mg PRN | Placebo |
|---|---|---|---|---|
| Started | 0 | 139 | 143 | 141 |
| Received at least 1 dose of study drug | 0 | 139 | 143 | 141 |
| Completed | 0 | 114 | 122 | 115 |
| Not completed | 0 | 25 | 21 | 26 |
| Withdrew: Adverse event | 0 | 10 | 6 | 4 |
| Withdrew: Withdrawal by subject | 0 | 7 | 3 | 3 |
| Withdrew: Lack of efficacy | 0 | 3 | 2 | 6 |
| Withdrew: Lost to follow-up | 0 | 3 | 0 | 4 |
| Withdrew: Entry criteria not met | 0 | 2 | 9 | 7 |
| Withdrew: Protocol deviation | 0 | 0 | 1 | 2 |
| Milestone | Screen - BNSRP | Tadalafil 5 mg OaD | Tadalafil 20 mg PRN | Placebo |
|---|---|---|---|---|
| Started | 0 | 114 | 122 | 115 |
| Completed | 0 | 105 | 117 | 108 |
| Not completed | 0 | 9 | 5 | 7 |
| Withdrew: Entry criteria not met | 0 | 2 | 1 | 2 |
| Withdrew: Lack of efficacy | 0 | 2 | 1 | 2 |
| Withdrew: Adverse event | 0 | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 | 2 |
| Withdrew: Physician decision | 0 | 1 | 1 | 0 |
| Withdrew: Sponsor decision | 0 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 | 2 | 0 |
| Withdrew: Death | 0 | 0 | 0 | 1 |
| Milestone | Screen - BNSRP | Tadalafil 5 mg OaD | Tadalafil 20 mg PRN | Placebo |
|---|---|---|---|---|
| Started | 0 | 105 | 117 | 108 |
| Completed | 0 | 98 | 112 | 105 |
| Not completed | 0 | 7 | 5 | 3 |
| Withdrew: Entry criteria not met | 0 | 2 | 0 | 0 |
| Withdrew: Lack of efficacy | 0 | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 | 2 | 1 |
| Withdrew: Protocol deviation | 0 | 1 | 3 | 1 |
| Withdrew: Withdrawal by subject | 0 | 2 | 0 | 1 |
Self-reported erectile function during the past 4 weeks. IIEF- EF is the sum of Questions 1-5 and 15 of the IIEF. Questions 1-5 are scored 0 (no sexual activity for Question 1, no sexual stimulation for Question 2 and did not attempt intercourse for Questions 3-5) to 5 (high erectile function) and Question 15 is scored 1 (very low confidence) to 5 (very high confidence), for a total score ranging from 1 to 30. Higher scores represent better erectile function. Data presented are the percentage of participants with an IIEF-EF Total Score greater than or equal to (≥) 22.
| percentage of participants | Tadalafil 5 mg OaD | Tadalafil 20 mg PRN | Placebo |
|---|---|---|---|
| Percentage of Participants With a Score of Greater Than or Equal to 22 in the Erectile Function (EF) Domain of the International Index of Erectile Function (IIEF) Questionnaire | 20.9 | 16.9 | 19.1 |
Self-reported erectile function during the past 4 weeks. IIEF- EF is the sum of Questions 1-5 and 15 of the IIEF. Questions 1-5 are scored 0 (no sexual activity for Question 1, no sexual stimulation for Question 2 and did not attempt intercourse for Questions 3-5) to 5 (high erectile function) and Question 15 is scored 1 (very low confidence) to 5 (very high confidence), for a total score ranging from 1 to 30. Higher scores represent better erectile function. Data presented are the percentage of participants with an IIEF-EF Total Score greater than or equal to (≥) 22.
| percentage of participants | Tadalafil 5 mg OaD | Tadalafil 20 mg PRN | Placebo |
|---|---|---|---|
| Month 9 | 25.2 | 19.7 | 14.2 |
| Month 13.5 | 32.4 | 33.1 | 27.0 |
Self-reported erectile function during the past 4 weeks. IIEF- EF is the sum of Questions 1-5 and 15 of the IIEF. Questions 1-5 are scored 0 (no sexual activity for Question 1, no sexual stimulation for Question 2 and did not attempt intercourse for Questions 3-5) to 5 (high erectile function) and Question 15 is scored 1 (very low confidence) to 5 (very high confidence), for a total score ranging from 1 to 30. Higher scores represent better erectile function. The Mixed Model for Repeated Measures (MMRM) analysis was used to calculate Least Squares (LS) mean and 95% confidence interval (CI). LS mean values are adjusted for baseline score, treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p\<0.10).
| units on a scale | Tadalafil 5 mg OaD | Tadalafil 20 mg PRN | Placebo |
|---|---|---|---|
| Month 9 | 7.73 (5.73 to 9.73) | 6.53 (4.56 to 8.50) | 4.93 (2.88 to 6.98) |
| Month 10.5 | 6.24 (4.22 to 8.25) | 5.76 (3.78 to 7.73) | 5.98 (3.92 to 8.03) |
| Month 13.5 | 10.60 (8.39 to 12.80) | 9.78 (7.63 to 11.92) | 8.97 (6.74 to 11.21) |
Self-reported overall satisfaction during past 4 weeks. Orgasmic function score is sum of Questions (Q)9 and 10 of IIEF. Scores range from 0 (no sexual stimulation or intercourse) to 5 (high orgasm) for each Q, total 0 to 10. Sexual desire score is sum of Q11 and 12 of IIEF. Scores range from 1 (low/no desire) to 5 (high desire) for each Q, total 2 to 10. Intercourse satisfaction score is sum of Q6, 7 and 8 of IIEF. Scores range from 0 (no attempts for Q6, did not attempt intercourse for Q7 and no intercourse for Q8) to 5 (high satisfaction) for each Q, total 0 to 15. Overall satisfaction score is sum of Q13 and 14 of IIEF. Scores range from 1 (low/no satisfaction) to 5 (high satisfaction) for each Q, total 2 to 10. Higher total scores for each domain indicate higher function. MMRM analysis was used to calculate LS mean and 95% CI. LS mean values are adjusted for baseline, treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p\<0.10).
| units on a scale | Tadalafil 5 mg OaD | Tadalafil 20 mg PRN | Placebo |
|---|---|---|---|
| Orgasmic function - Month 9 | 2.76 (1.98 to 3.55) | 2.48 (1.70 to 3.26) | 2.39 (1.59 to 3.19) |
| Orgasmic function - Month 10.5 | 2.94 (2.13 to 3.76) | 2.48 (1.68 to 3.28) | 2.48 (1.66 to 3.31) |
| Orgasmic function - Month 13.5 | 3.57 (2.75 to 4.39) | 2.90 (2.10 to 3.70) | 3.42 (2.59 to 4.25) |
| Sexual desire - Month 9 | 0.65 (0.18 to 1.12) | 0.65 (0.18 to 1.11) | 0.63 (0.15 to 1.11) |
| Sexual desire - Month 10.5 | 0.61 (0.14 to 1.07) | 0.65 (0.20 to 1.11) | 0.55 (0.08 to 1.01) |
| Sexual desire - Month 13.5 | 1.04 (0.56 to 1.52) | 0.89 (0.42 to 1.35) | 0.95 (0.46 to 1.43) |
| Intercourse satisfaction - Month 9 | 3.89 (2.90 to 4.88) | 3.50 (2.52 to 4.48) | 2.96 (1.95 to 3.96) |
| Intercourse satisfaction - Month 10.5 | 3.21 (2.19 to 4.22) | 2.81 (1.81 to 3.81) | 2.72 (1.69 to 3.75) |
| Intercourse satisfaction - Month 13.5 | 4.70 (3.65 to 5.75) | 4.08 (3.05 to 5.10) | 4.14 (3.08 to 5.20) |
| Overall satisfaction - Month 9 | 0.97 (0.38 to 1.56) | 0.93 (0.35 to 1.51) | 0.78 (0.18 to 1.38) |
| Overall satisfaction - Month 10.5 | 0.64 (0.05 to 1.23) | 0.48 (-0.10 to 1.06) | 0.72 (0.12 to 1.32) |
| Overall satisfaction - Month 13.5 | 1.50 (0.87 to 2.13) | 1.57 (0.96 to 2.19) | 1.52 (0.88 to 2.15) |
The EDITS questionnaire is a validated questionnaire consisting of 11 questions evaluating self-reported satisfaction with the erectile dysfunction (ED) treatment. Responses were based on the experiences during the previous 4 weeks. Each question is rated on a scale of 0 (extremely low treatment satisfaction) to 4 (extremely high treatment satisfaction). The EDITS mean score was obtained by adding each individual result for all questions, dividing by the number of questions answered. The mean scores range from 0 (extremely low treatment satisfaction) to 4 (extremely high satisfaction). The Mixed Model for Repeated Measures (MMRM) analysis was used to calculate Least Squares (LS) mean and 95% Confidence Interval (CI). LS mean values are adjusted for treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p\<0.10).
| units on a scale | Tadalafil 5 mg OaD | Tadalafil 20 mg PRN | Placebo |
|---|---|---|---|
| Month 9 | 2.21 ± 0.11 | 2.11 (1.92 to 2.30) | 1.88 (1.67 to 2.09) |
| Month 13.5 | 2.54 (2.31 to 2.77) | 2.38 (2.17 to 2.59) | 2.25 (2.03 to 2.48) |
The SEAR questionnaire is a participant-reported measure of psychosocial outcomes in men with erectile dysfunction (ED). It consists of 14 items. Sexual Relationship domain consists of 8 items (items 1-8). Items 2-8 are rated on a scale of 1 (Never) to 5 (Always), whereas item 1 is reverse scored (1=Always and 5=Never). The total scores for sexual relationship domain range from 8-40 with higher scores indicating better relationship. Self-Esteem subdomain contains items 9 through 12 rated on a scale of 1 (no/low self-esteem) to 5 (high self-esteem). Total scores for Self-Esteem subscale range from 4-20 with higher scores indicating higher self-esteem. The Mixed Model for Repeated Measures (MMRM) analysis was used to calculate Least Squares (LS) mean and 95% Confidence Interval (CI). LS mean values are adjusted for baseline domain score, treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p\<0.10).
| units on a scale | Tadalafil 5 mg OaD | Tadalafil 20 mg PRN | Placebo |
|---|---|---|---|
| Sexual relationship - Month 9 | 4.78 (2.87 to 6.68) | 3.50 (1.61 to 5.38) | 3.02 (1.09 to 4.95) |
| Sexual relationship - Month 13.5 | 6.90 (4.79 to 9.00) | 6.68 (4.62 to 8.74) | 6.72 (4.62 to 8.83) |
| Self-esteem - Month 9 | 0.78 (-0.31 to 1.87) | 0.79 (-0.29 to 1.87) | 0.51 (-0.61 to 1.62) |
| Self-esteem - Month 13.5 | 1.67 (0.54 to 2.81) | 1.72 (0.61 to 2.83) | 1.62 (0.47 to 2.77) |
GAQ Question 1: Choose the one number which best describes how you perceive your ability to achieve and maintain your erections now, compared to how it was before you began taking medication in this study. Responses range from very much better (1) to very much worse (7).
| participants | Tadalafil 5 mg OaD | Tadalafil 20 mg PRN | Placebo |
|---|---|---|---|
| Very much better | 9 | 10 | 4 |
| Much better | 12 | 22 | 9 |
| A little better | 33 | 32 | 22 |
| No change | 31 | 28 | 48 |
| A little worse | 4 | 5 | 3 |
| Much worse | 6 | 8 | 6 |
| Very much worse | 8 | 11 | 14 |
| Missing | 11 | 6 | 9 |
GAQ Question 1: Choose the one number which best describes how you perceive your ability to achieve and maintain your erections now, compared to how it was before you began taking medication in this study. Responses range from very much better (1) to very much worse (7).
| participants | Tadalafil 5 mg OaD | Tadalafil 20 mg PRN | Placebo |
|---|---|---|---|
| Very much better | 13 | 19 | 16 |
| Much better | 24 | 25 | 18 |
| A little Better | 28 | 27 | 28 |
| No Change | 19 | 23 | 26 |
| A little worse | 4 | 4 | 2 |
| Much worse | 3 | 3 | 5 |
| Very much worse | 5 | 6 | 6 |
| Missing | 4 | 7 | 5 |
GAQ Question 2: Choose the one number which best describes how you perceive your sexual life is now, compared to how it was before you began taking medication in this study. Responses range from very much better (1) to very much worse (7).
| participants | Tadalafil 5 mg OaD | Tadalafil 20 mg PRN | Placebo |
|---|---|---|---|
| Very much better | 7 | 7 | 3 |
| Much better | 12 | 25 | 11 |
| A little better | 30 | 26 | 18 |
| No change | 31 | 27 | 49 |
| A little worse | 8 | 10 | 4 |
| Much worse | 7 | 10 | 10 |
| Very much worse | 9 | 9 | 11 |
| Missing | 10 | 8 | 9 |
GAQ Question 2: Choose the one number which best describes how you perceive your sexual life is now, compared to how it was before you began taking medication in this study. Responses range from very much better (1) to very much worse (7).
| participants | Tadalafil 5 mg OaD | Tadalafil 20 mg PRN | Placebo |
|---|---|---|---|
| Very much better | 9 | 20 | 14 |
| Much better | 29 | 23 | 21 |
| A little better | 20 | 26 | 24 |
| No change | 25 | 24 | 26 |
| A little worse | 4 | 5 | 5 |
| Much worse | 4 | 3 | 7 |
| Very much worse | 5 | 6 | 4 |
| Missing | 4 | 7 | 5 |
The participant is asked to rate the hardness of his erection using a 5-point grading system, with 0 (penis does not enlarge), 1 (penis is larger but not hard), 2 (penis is hard but not enough for penetration), 3 (penis is hard enough for penetration but not completely hard), 4 (penis is completely hard and fully rigid.)
| participants | Tadalafil 5 mg OaD | Tadalafil 20 mg PRN | Placebo |
|---|---|---|---|
| REF = 0 | 61 | 62 | 64 |
| REF = 1 | 46 | 48 | 47 |
| REF = 2 | 18 | 17 | 17 |
| REF = 3 | 12 | 11 | 13 |
| REF = 4 | 0 | 2 | 0 |
| Missing | 2 | 2 | 0 |
The participant is asked to rate the hardness of his erection using a 5-point grading system, with 0 (penis does not enlarge), 1 (penis is larger but not hard), 2 (penis is hard but not enough for penetration), 3 (penis is hard enough for penetration but not completely hard), 4 (penis is completely hard and fully rigid.)
| participants | Tadalafil 5 mg OaD | Tadalafil 20 mg PRN | Placebo |
|---|---|---|---|
| REF = 0 | 28 | 27 | 38 |
| REF = 1 | 38 | 51 | 53 |
| REF = 2 | 26 | 28 | 19 |
| REF = 3 | 25 | 23 | 15 |
| REF = 4 | 9 | 5 | 5 |
| Missing | 13 | 8 | 11 |
The participant is asked to rate the hardness of his erection using a 5-point grading system, with 0 (penis does not enlarge), 1 (penis is larger but not hard), 2 (penis is hard but not enough for penetration), 3 (penis is hard enough for penetration but not completely hard), 4 (penis is completely hard and fully rigid.)
| participants | Tadalafil 5 mg OaD | Tadalafil 20 mg PRN | Placebo |
|---|---|---|---|
| REF = 0 | 12 | 21 | 27 |
| REF = 1 | 37 | 39 | 35 |
| REF = 2 | 19 | 21 | 27 |
| REF = 3 | 32 | 34 | 19 |
| REF = 4 | 15 | 6 | 6 |
| Missing | 8 | 7 | 9 |
The participant is asked to rate the hardness of his erection using a 5-point grading system, with 0 (penis does not enlarge), 1 (penis is larger but not hard), 2 (penis is hard but not enough for penetration), 3 (penis is hard enough for penetration but not completely hard), 4 (penis is completely hard and fully rigid.)
| participants | Tadalafil 5 mg OaD | Tadalafil 20 mg PRN | Placebo |
|---|---|---|---|
| REF = 0 | 11 | 17 | 23 |
| REF = 1 | 25 | 28 | 35 |
| REF = 2 | 22 | 30 | 23 |
| REF = 3 | 23 | 27 | 18 |
| REF = 4 | 20 | 15 | 10 |
| Missing | 13 | 5 | 6 |
The participant is asked to rate the hardness of his erection using a 5-point grading system, with 0 (penis does not enlarge), 1 (penis is larger but not hard), 2 (penis is hard but not enough for penetration), 3 (penis is hard enough for penetration but not completely hard), 4 (penis is completely hard and fully rigid.)
| participants | Tadalafil 5 mg OaD | Tadalafil 20 mg PRN | Placebo |
|---|---|---|---|
| REF = 0 | 13 | 17 | 22 |
| REF = 1 | 29 | 30 | 29 |
| REF = 2 | 25 | 23 | 19 |
| REF = 3 | 22 | 31 | 22 |
| REF = 4 | 12 | 10 | 14 |
| Missing | 4 | 6 | 2 |
The participant is asked to rate the hardness of his erection using a 5-point grading system, with 0 (penis does not enlarge), 1 (penis is larger but not hard), 2 (penis is hard but not enough for penetration), 3 (penis is hard enough for penetration but not completely hard), 4 (penis is completely hard and fully rigid.)
| participants | Tadalafil 5 mg OaD | Tadalafil 20 mg PRN | Placebo |
|---|---|---|---|
| REF = 0 | 5 | 8 | 11 |
| REF = 1 | 19 | 20 | 25 |
| REF = 2 | 17 | 20 | 15 |
| REF = 3 | 34 | 34 | 28 |
| REF = 4 | 21 | 28 | 24 |
| Missing | 4 | 4 | 3 |
Participant-assessed diary has 5 questions: Question (Q)1: erection achievement, Q2: successful penetration, Q3: successful intercourse, Q4: satisfied with erection, and Q5: satisfied with sexual experience) for each sexual encounter made over a specified period of time. SEP Q1-Q5 scores were determined as the percentage of 'Yes' responses to each of the 5 questions out of all sexual attempts recorded during the time period. The Mixed Model for Repeated Measures (MMRM) analysis was used to calculate Least Squares (LS) mean and 95% confidence interval (CI). LS mean values are adjusted for treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p\<0.10).
| percentage of "yes" responses | Tadalafil 5 mg OaD | Tadalafil 20 mg PRN | Placebo |
|---|---|---|---|
| Q1 - Month 9 | 67.41 (58.29 to 76.54) | 63.88 (55.32 to 72.44) | 52.54 (43.62 to 61.46) |
| Q1 - Month 10.5 | 67.78 (58.05 to 77.50) | 64.24 (55.06 to 73.41) | 58.86 (49.15 to 68.58) |
| Q1 - Month 13.5 | 86.16 (77.82 to 94.51) | 79.79 (71.93 to 87.65) | 75.27 (66.93 to 83.60) |
| Q2 - Month 9 | 44.00 (35.22 to 52.78) | 34.29 (26.03 to 42.56) | 27.67 (19.11 to 36.23) |
| Q2 - Month 10.5 | 40.81 (31.21 to 50.40) | 34.99 (25.91 to 44.08) | 36.26 (26.67 to 45.85) |
| Q2 - Month 13.5 | 63.48 (53.87 to 73.09) | 56.07 (46.91 to 65.24) | 50.11 (40.56 to 59.67) |
| Q3 - Month 9 | 33.67 (25.47 to 41.86) | 24.09 (16.36 to 31.82) | 21.61 (13.62 to 29.59) |
| Q3 - Month 10.5 | 28.75 (19.92 to 37.57) | 23.01 (14.65 to 31.37) | 28.52 (19.68 to 37.36) |
| Q3 - Month 13.5 | 52.41 (42.80 to 62.02) | 45.83 (36.63 to 55.04) | 40.75 (31.18 to 50.31) |
| Q4 - Month 9 | 26.17 (18.93 to 33.40) | 18.15 (11.31 to 24.99) | 14.30 (7.25 to 21.35) |
| Q4 - Month 10.5 | 16.94 (9.66 to 24.23) | 11.74 (4.84 to 18.64) | 18.88 (11.54 to 26.22) |
| Q4 - Month 13.5 | 42.08 (32.99 to 51.18) | 35.62 (26.88 to 44.37) | 30.56 (21.48 to 39.65) |
| Q5 - Month 9 | 25.42 (18.29 to 32.55) | 17.73 (10.99 to 24.47) | 14.04 (7.09 to 20.99) |
| Q5 - Month 10.5 | 16.26 (9.21 to 23.31) | 10.52 (3.85 to 17.19) | 19.11 (12.00 to 26.23) |
| Q5 - Month 13.5 | 40.81 (31.82 to 49.81) | 34.96 (26.31 to 43.62) | 29.38 (20.39 to 38.37) |
The participants were asked to complete the morning erections diary every morning during the 4-week period before randomization and during the 6-week, Drug-Free, Washout Period. Data presented are the changes in the participant's percentage of "yes" responses relative to the number of days the question was answered during treatment. The analysis of covariance (ANCOVA) was used to calculate Least Square (LS) mean and 95% confidence interval (CI). LS mean values are adjusted for treatment, baseline morning erections frequency, age group and country.
| percentage of "yes" response | Tadalafil 5 mg OaD | Tadalafil 20 mg PRN | Placebo |
|---|---|---|---|
| Change From Baseline in 'Yes' Answers to Morning Erections | 8.92 (1.45 to 16.39) | 12.16 (5.16 to 19.16) | 14.04 (6.74 to 21.35) |
Participants evaluated the frequency of their morning erections during the past 3-month period by answering the SMEQ ("Do you ever wake up with an erection") using a 4-point grading system ranging from 0 (Yes, regularly) to 3 (never).
| participants | Tadalafil 5 mg OaD | Tadalafil 20 mg PRN | Placebo |
|---|---|---|---|
| Yes, regularly | 4 | 7 | 7 |
| Less frequently than in the past | 8 | 15 | 10 |
| Only occasionally | 41 | 31 | 26 |
| Never | 73 | 80 | 87 |
| Missing | 13 | 9 | 11 |
Participants evaluated the frequency of their morning erections during the past 3-month period by answering the SMEQ ("Do you ever wake up with an erection") using a 4-point grading system ranging from 0 (Yes, regularly) to 3 (never).
| participants | Tadalafil 5 mg OaD | Tadalafil 20 mg PRN | Placebo |
|---|---|---|---|
| Yes, regularly | 7 | 9 | 7 |
| Less frequently than in the past | 21 | 19 | 9 |
| Only occasionally | 36 | 26 | 27 |
| Never | 39 | 61 | 65 |
| Missing | 11 | 7 | 7 |
Participants evaluated the frequency of their morning erections during the past 3-month period by answering the SMEQ ("Do you ever wake up with an erection") using a 4-point grading system ranging from 0 (Yes, regularly) to 3 (never).
| participants | Tadalafil 5 mg OaD | Tadalafil 20 mg PRN | Placebo |
|---|---|---|---|
| Yes, regularly | 13 | 15 | 13 |
| Less frequently than in the past | 22 | 24 | 18 |
| Only occasionally | 31 | 30 | 27 |
| Never | 32 | 40 | 42 |
| Missing | 2 | 5 | 6 |
EPIC-26 (participants) contains 26 items and 5 domains: Urinary Incontinence (Items 1-4), Urinary Irritative/Obstructive (Items 5-8), Bowel (Items 10-15), Sexual (Items 16-21), and Hormonal (Items 22-26). Response options for each EPIC item form a Likert scale, and multi-item scale scores are transformed linearly to a 0 to 100 scale for each domain, with higher scores representing better health-related quality of life. Responses are based on experiences during the previous 4 weeks. The Mixed Model for Repeated Measures (MMRM) analysis was used to calculate Least Squares (LS) mean and 95% confidence interval (CI). LS mean values are adjusted for baseline domain score, treatment, country, visit, visit-by-treatment, age group, and age group-by-treatment (if significant at p\<0.10).
| units on a scale | Tadalafil 5 mg OaD | Tadalafil 20 mg PRN | Placebo |
|---|---|---|---|
| Urinary Incontinence - Month 9 | 34.08 (29.31 to 38.86) | 31.12 (26.74 to 35.51) | 30.59 (25.85 to 35.33) |
| Urinary Incontinence - Month 13.5 | 37.41 (32.56 to 42.26) | 35.54 (31.10 to 39.97) | 35.44 (30.65 to 40.23) |
| Urinary Irritative/Obstructive - Month 9 | 13.83 (11.54 to 16.12) | 13.28 (11.19 to 15.37) | 12.26 (10.01 to 14.51) |
| Urinary Irritative/Obstructive - Month 13.5 | 13.86 (11.53 to 16.20) | 13.82 (11.70 to 15.94) | 12.30 (0.01 to 14.60) |
| Bowel - Month 9 | 5.94 (3.71 to 8.17) | 6.27 (4.22 to 8.33) | 6.48 (4.31 to 8.65) |
| Bowel - Month 13.5 | 6.87 (4.67 to 9.08) | 6.49 (4.46 to 8.52) | 6.78 (4.61 to 8.94) |
| Sexual - Month 9 | 27.53 (21.64 to 33.42) | 20.66 (15.27 to 26.06) | 17.98 (12.14 to 23.81) |
| Sexual - Month 13.5 | 36.55 (30.03 to 43.06) | 32.58 (26.60 to 38.56) | 33.37 (26.95 to 39.79) |
| Hormonal - Month 9 | 1.72 (-0.81 to 4.26) | 2.72 (0.36 to 5.08) | -0.18 (-2.67 to 2.31) |
| Hormonal - Month 13.5 | 2.48 (0.10 to 4.87) | 2.92 (0.76 to 5.08) | 3.01 (0.67 to 5.36) |
Measurements were performed with the penis in the flaccid state. The stretched penile length was measured from the tip of the glans to the pubopenile skin junction while applying tension to maximally stretch the penis. The penile circumference at midshaft was measured. All measurements were taken with a paper ruler to the nearest 0.5 centimeter (cm). The analysis of covariance (ANCOVA) was used to calculate Least Square (LS) mean and 95% confidence interval (CI). LS mean values are adjusted for treatment, baseline, age group and country.
| millimeter (mm) | Tadalafil 5 mg OaD | Tadalafil 20 mg PRN | Placebo |
|---|---|---|---|
| Length | -1.53 (-5.54 to 2.47) | -7.26 (-11.04 to -3.49) | -5.73 (-9.68 to -1.78) |
| Girth | 0.03 (-3.09 to 3.15) | 0.82 (-2.11 to 3.75) | -2.34 (-5.43 to 0.75) |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Screen - BNSRP | — | 6/583 (1%) | 114/583 (19.6%) |
| Tadalafil 5 mg OaD (Double-Blind Period/Washout Period) | — | 2/139 (1.4%) | 50/139 (36%) |
| Tadalafil 20 mg PRN (Double-Blind Period/Washout Period) | — | 3/143 (2.1%) | 52/143 (36.4%) |
| Placebo (Double-Blind Period/Washout Period) | — | 10/141 (7.1%) | 40/141 (28.4%) |
| Tadalafil 5 mg OaD (Open-Label Period) | — | 1/139 (0.7%) | 11/139 (7.9%) |
| Tadalfil 20 mg PRN (Open-Label Period) | — | 1/143 (0.7%) | 18/143 (12.6%) |
| Placebo (Open-Label Period) | — | 2/141 (1.4%) | 9/141 (6.4%) |
| Event | Screen - BNSRP | Tadalafil 5 mg OaD (Double-Blind Period/Washout Period) | Tadalafil 20 mg PRN (Double-Blind Period/Washout Period) | Placebo (Double-Blind Period/Washout Period) | Tadalafil 5 mg OaD (Open-Label Period) | Tadalfil 20 mg PRN (Open-Label Period) | Placebo (Open-Label Period) |
|---|---|---|---|---|---|---|---|
| SplenomegalyBlood and lymphatic system disorders | 0/583 | 1/139 | 0/143 | 0/141 | 0/139 | 0/143 | 0/141 |
| PyrexiaGeneral disorders | 0/583 | 1/139 | 0/143 | 0/141 | 0/139 | 0/143 | 0/141 |
| Drug hypersensitivityImmune system disorders | 0/583 | 1/139 | 0/143 | 0/141 | 0/139 | 0/143 | 0/141 |
| Intentional overdoseInjury, poisoning and procedural complications | 0/583 | 0/139 | 0/143 | 0/141 | 1/139 | 0/143 | 0/141 |
| Acute myocardial infarctionCardiac disorders | 0/583 | 0/139 | 0/143 | 1/141 | 0/139 | 0/143 | 0/141 |
| Rectal haemorrhageGastrointestinal disorders | 0/583 | 0/139 | 0/143 | 1/141 | 0/139 | 0/143 | 0/141 |
| Abdominal abscessInfections and infestations | 0/583 | 0/139 | 0/143 | 1/141 | 0/139 | 0/143 | 0/141 |
| ErysipelasInfections and infestations | 0/583 | 0/139 | 0/143 | 0/141 | 0/139 | 0/143 | 1/141 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 0/583 | 0/139 | 0/143 | 1/141 | 0/139 | 0/143 | 0/141 |
| Rotator cuff syndromeMusculoskeletal and connective tissue disorders | 0/583 | 0/139 | 0/143 | 1/141 | 0/139 | 0/143 | 0/141 |
| Event | Screen - BNSRP | Tadalafil 5 mg OaD (Double-Blind Period/Washout Period) | Tadalafil 20 mg PRN (Double-Blind Period/Washout Period) | Placebo (Double-Blind Period/Washout Period) | Tadalafil 5 mg OaD (Open-Label Period) | Tadalfil 20 mg PRN (Open-Label Period) | Placebo (Open-Label Period) |
|---|---|---|---|---|---|---|---|
| HeadacheNervous system disorders | 9/583 | 5/139 | 11/143 | 6/141 | 1/139 | 2/143 | 1/141 |
| Urinary incontinenceRenal and urinary disorders | 34/583 | 3/139 | 0/143 | 0/141 | 0/139 | 0/143 | 0/141 |
| Urinary tract infectionInfections and infestations | 21/583 | 3/139 | 4/143 | 2/141 | 1/139 | 0/143 | 0/141 |
| DyspepsiaGastrointestinal disorders | 0/583 | 5/139 | 5/143 | 1/141 | 1/139 | 1/143 | 0/141 |
| NasopharyngitisInfections and infestations | 2/583 | 5/139 | 5/143 | 3/141 | 0/139 | 1/143 | 0/141 |
| Back painMusculoskeletal and connective tissue disorders | 1/583 | 5/139 | 5/143 | 3/141 | 0/139 | 1/143 | 1/141 |
| MyalgiaMusculoskeletal and connective tissue disorders | 5/583 | 5/139 | 5/143 | 1/141 | 0/139 | 0/143 | 1/141 |
| Seasonal allergyImmune system disorders | 0/583 | 4/139 | 0/143 | 0/141 | 0/139 | 0/143 | 0/141 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 2/583 | 3/139 | 4/143 | 0/141 | 0/139 | 0/143 | 1/141 |
| Procedural painInjury, poisoning and procedural complications | 13/583 | 0/139 | 1/143 | 1/141 | 0/139 | 0/143 | 0/141 |
All randomized participants who received at least 1 dose of study drug.
| Age, Continuous(years) | Tadalafil 5 mg OaD | Tadalafil 20 mg PRN | Placebo | Total |
|---|---|---|---|---|
| Mean | 58.6 ± 5.07 | 57.5 ± 5.91 | 57.6 ± 5.69 | 57.9 ± 5.58 |
| Sex: Female, Male(Participants) | Tadalafil 5 mg OaD | Tadalafil 20 mg PRN | Placebo | Total |
|---|---|---|---|---|
| Female | 0 | 0 | 0 | 0 |
| Male | 139 | 143 | 141 | 423 |
| Race/Ethnicity, Customized(participants) | Tadalafil 5 mg OaD | Tadalafil 20 mg PRN | Placebo | Total |
|---|---|---|---|---|
| White | 137 | 141 | 138 | 416 |
| American Indian or Alaska Native | 0 | 1 | 0 | 1 |
| Asian | 0 | 0 | 1 | 1 |
| Black or African American | 2 | 1 | 2 | 5 |
| Region of Enrollment(participants) | Tadalafil 5 mg OaD | Tadalafil 20 mg PRN | Placebo | Total |
|---|---|---|---|---|
| France | 12 | 13 | 13 | 38 |
| Canada | 13 | 13 | 12 | 38 |
| Belgium | 7 | 9 | 8 | 24 |
| Poland | 10 | 9 | 8 | 27 |
| Spain | 38 | 39 | 39 | 116 |
| Germany | 26 | 25 | 27 | 78 |
| Netherlands | 0 | 2 | 1 | 3 |
| United Kingdom | 7 | 8 | 8 | 23 |
| Switzerland | 1 | 1 | 1 | 3 |
| Italy | 25 | 24 | 24 | 73 |
The record gives a start of Nov 2009, a primary completion of Oct 2012 and a completion of Oct 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2013, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tadalafil